PDGF signaling pathway in hepatic fibrosis pathogenesis and therapeutics
Molecular Medicine Reports2017Vol. 16(6), pp. 7879–7889
Citations Over TimeTop 10% of 2017 papers
Huazhong Ying, Qin Chen, Wenyou Zhang, Huan‐Huan Zhang, Yue Ma, Songzhao Zhang, Jie Fang, Chen-Huan Yu
Abstract
The platelet‑derived growth factor (PDFG) signaling pathway exerts persistent activation in response to a variety of stimuli and facilitates the progression of hepatic fibrosis. Since this pathway modulates a broad spectrum of cellular processes, including cell growth, differentiation, inflammation and carcinogenesis, it has emerged as a therapeutic target for hepatic fibrosis and liver‑associated disorders. The present review exhibits the current knowledge of the role of the PDGF signaling pathway and its pathological profiles in hepatic fibrosis, and assesses the potential of inhibitors which have been investigated in the experimental hepatic fibrosis model, in addition to the clinical challenges associated with these inhibitors.
Related Papers
- → A Selective PPARγ Modulator Reduces Hepatic Fibrosis(2020)6 cited
- → Non-Invasively Distinguishing Progress of Liver Fibrosis by Visualizing Hepatic Platelet Derived Growth Factor Receptor-Beta Expression with an MRI Modality in Mice(2020)1 cited
- → Effects of suramin on proliferation and apoptosis of hepatic stellate cells of hepatic fibrosis rats(2011)
- Effectiveness of saponins from Panax notoginseng against hepatic fibrosis(2007)
- → Research progress on the relationship between transforming growth factor-β1 and hepatic fibrosis(2017)